Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Hulu’s The Testaments casts its Daisy, a Canadian teen whose world is upended when she discovers her hidden connection to ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...